CHIlled Platelet Study "CHIPS" (CHIPS)
CHIlled Platelet Study
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Fiona Stanley Hospital
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
Arizona
-
Pheonix, Arizona, United States, 85054
- Mayo Clinic Arizona
-
Tuscon, Arizona, United States, 85713
- Banner University Medical Center
-
-
California
-
Los Angeles, California, United States, 90095
- Ronald Reagan UCLA Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 32608
- University of Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
Maywood, Illinois, United States, 60153
- Loyola Universtiy Medical Center
-
-
Kansas
-
Kansas City, Kansas, United States, 66103
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- John Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02910
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, United States, 75235
- University of Texas Children's Medical Center
-
Dallas, Texas, United States, 75235
- University of Texas Medical Center Clements
-
Houston, Texas, United States, 77030
- Memorial Hermann Texas Medical Center
-
Houston, Texas, United States, 77030
- Baylor Texas Children's
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin- Madison
-
Milwaukee, Wisconsin, United States, 53226
- Children's Hospital of Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Aurora St. Luke's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
- Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring platelet transfusion.
Exclusion Criteria:
- Expected order for washed or volume reduced platelets
- Patient with known anti-platelet antibodies
- Platelet transfusion refractoriness due to anti-HLA antibodies
- Known or suspected pregnancy
- Previously randomized in this study
- Conscious objection or unwillingness to receive blood products
- Known IgA deficiency
- Known congenital platelet disorder
- Known congenital bleeding disorder
- Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
- Patients intended to receive whole blood either intra-operative or post-operative for bleeding
- Platelet transfusion (of any type) within 24 hours prior to the date of surgery
- Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Room Temperature Platelets
Platelets stored at 20-24 degrees Celsius |
Platelets stored at 20-24 degrees Celsius |
|
Experimental: Cold Stored Platelets
Platelets stored at 1-6 degree Celsius |
Platelets stored at 1-6 degree Celsius |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemostatic Efficacy
Time Frame: 24 hours after first study platelet transfusion
|
Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome. |
24 hours after first study platelet transfusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chest Tube Output Through 24 Hours
Time Frame: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Chest tube output will be assessed by volume |
24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Product Administration
Time Frame: 24 and 72 hours from start time of first study platelet transfusion
|
The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood |
24 and 72 hours from start time of first study platelet transfusion
|
|
Transfusion Associated Adverse Events
Time Frame: within 7 days of first study platelet transfusion
|
As per CDC guidelines for transfusion associated adverse events |
within 7 days of first study platelet transfusion
|
|
Arterial Thrombotic Event
Time Frame: within 7 days of first study platelet transfusion
|
Stroke, MI, aortic thromboic even |
within 7 days of first study platelet transfusion
|
|
Venous Thrombotic Event
Time Frame: within 7 days of first study platelet transfusion
|
Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram |
within 7 days of first study platelet transfusion
|
|
All Cause Mortality
Time Frame: up to 28 days
|
Death for any reason |
up to 28 days
|
|
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Time Frame: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Time Frame: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Time Frame: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Time Frame: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid |
24 and 72 hours from start time of first study platelet transfusion
|
|
Mechanical Ventilation
Time Frame: up to 28 days after first study platelet transfusion
|
Number of participants with need for mechanical ventilation |
up to 28 days after first study platelet transfusion
|
|
Length of Stay
Time Frame: up to 28 days
|
ICU and hospital length of stay |
up to 28 days
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Time Frame: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Time Frame: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement). |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Time Frame: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Time Frame: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Time Frame: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Time Frame: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Unplanned Sternal Closure Delay
Time Frame: prior to ICU admission
|
Sternum left open after cardiac surgery |
prior to ICU admission
|
|
Re-exploration for Bleeding
Time Frame: 24 hours first study platelet transfusion
|
Return to OR after ICU admission |
24 hours first study platelet transfusion
|
|
Unplanned Extracorporeal Support Post Operatively
Time Frame: within 48 hours of first study platelet transfusion
|
Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion |
within 48 hours of first study platelet transfusion
|
|
Morbidities After ICU Admission
Time Frame: within 7 days of first study platelet transfusion
|
Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock |
within 7 days of first study platelet transfusion
|
|
Measures of End Organ Injury- BUN and Creatinine
Time Frame: within 48 hours of first study platelet transfusion worst value
|
If BUN, creatinine are collected clinically.- worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Lactate
Time Frame: within 48 hours of first study platelet transfusion worst value
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Troponin
Time Frame: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
|
Measures of End Organ Injury- ALT and AST
Time Frame: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Philip C Spinella, MD, University of Pittsburgh
- Study Director: Marie E Steiner, MD, University of Minnesota
- Study Director: Nicole D Zantek, MD, University of Minnesota
Publications and helpful links
General Publications
- Krachey E, Viele K, Spinella PC, Steiner ME, Zantek ND, Lewis RJ. The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients. J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S41-S46. doi: 10.1097/TA.0000000000001876.
- Strandenes G, Sivertsen J, Bjerkvig CK, Fosse TK, Cap AP, Del Junco DJ, Kristoffersen EK, Haaverstad R, Kvalheim V, Braathen H, Lunde THF, Hervig T, Hufthammer KO, Spinella PC, Apelseth TO. A Pilot Trial of Platelets Stored Cold versus at Room Temperature for Complex Cardiothoracic Surgery. Anesthesiology. 2020 Dec 1;133(6):1173-1183. doi: 10.1097/ALN.0000000000003550.
- Zantek ND, Steiner ME, VanBuren JM, Lewis RJ, Berry NS, Viele K, Krachey E, Dean JM, Nelson S, Spinella PC. Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet Study. Clin Trials. 2023 Feb;20(1):36-46. doi: 10.1177/17407745221126423. Epub 2022 Dec 21.
- Spinella PC, Zantek ND, VanBuren JM, Nicolson SC, Khanna AK, Klompas AM, Boisen ML, Williams TM, Monteleone M, Bashir DA, Pavey W, Smith BB, Ahmed MI, Niebler RA, Jeng E, Flynn BC, Joshi RV, Preuss JF, Goswami D, Yamada C, Lewis C, Cohn CS, Tint H, Kwak J, Sodha N, Simon ER, Van PY, Greilich PE, Booth FVM, Carter CP, Keegan A, Cap AP, Matuk J, McGlothlin A, Berry NS, Lewis RJ, Steiner ME; CHIPS Investigator Group. Cold and Room-Temperature Platelets in Cardiac Surgery: The CHIPS Randomized Clinical Trial. JAMA. 2026 Aug 17. doi: 10.1001/jama.2026.13328. Online ahead of print.
- Lewis AR, Peffley N, Klompas AM, Ashrani AA. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency. Transfusion. 2023 Sep;63(9):1773-1777. doi: 10.1111/trf.17477. Epub 2023 Jul 10.
- Klompas AM, Stubbs J. Massive transfusion protocol: What's in a name? Transfusion. 2023 Apr;63(4):896-897. doi: 10.1111/trf.17297. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHIPS
- W81XWH2090021 (Other Grant/Funding Number: DoD)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.